ASX - Delayed Quote ? AUD Neuren Pharmaceuticals Limited (NEU.AX) Follow Compare 13.13 +0.02 (+0.15%) At close: October 18 at 4:10 PM GMT+11 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 Undervalued Small Caps In Australia With Insider Buying Over the last 7 days, the Australian market has risen 1.7%, driven by gains of 12% in the Materials sector, although the Financials sector is down 3.2%. Over the past 12 months, the market is up 17%, with earnings forecast to grow by 12% annually. In this context, identifying undervalued small-cap stocks with insider buying can be a strategic move for investors looking to capitalize on potential growth opportunities within a robust market environment. Simply Wall St. ? 18 days ago SMSMY SMUPF APE.AX 3 Undervalued Small Caps In Australia With Insider Action In the last week, the Australian market has stayed flat, with notable gains of 9.0% in the Materials sector. Over the past year, the market is up 16%, and earnings are forecast to grow by 12% annually. In this context, identifying undervalued small-cap stocks with insider action can offer promising opportunities for investors looking to capitalize on potential growth within a stable market environment. Simply Wall St. ? 19 days ago NURPF CTMLF APE.AX 3 Undervalued Small Caps In Australia With Recent Insider Activity As the Australian market continues to show mixed performance, with the ASX200 closing up 0.1% at 8,212 points and notable gains in the Materials sector, investors are increasingly looking for opportunities beyond the big miners and banks. In this context, small-cap stocks with recent insider activity can present intriguing investment possibilities, especially when they appear undervalued amidst broader market movements. Identifying such stocks requires careful consideration of their... Simply Wall St. ? 20 days ago NURPF CTMLF SMSMY Top Undervalued Small Caps With Insider Action In Australia For September 2024 As the ASX200 edges closer to its all-time high, buoyed by positive sentiment from Wall Street and optimism around potential US Fed rate cuts, Australian markets are experiencing a mixed performance across various sectors. While Discretionary and Utilities have shown gains, Real Estate has lagged behind, reflecting the nuanced landscape that investors must navigate. In this environment, identifying undervalued small-cap stocks with insider action becomes crucial for discerning investors... Simply Wall St. ? 27 days ago SMSMY SMUPF NURPF Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% The last three months have been tough on Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders, who have seen the... Simply Wall St. ? last month NURPF Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models Neuren Pharmaceuticals Limited ( ASX:NEU ) came out with its interim results last week, and we wanted to see how the... Simply Wall St. ? last month NURPF Neuren Pharmaceuticals Limited's (ASX:NEU) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? With its stock down 28% over the past three months, it is easy to disregard Neuren Pharmaceuticals (ASX:NEU). However... Simply Wall St. ? 2 months ago NURPF Exploring Undervalued Small Caps With Insider Insights In Australia July 2024 The Australian market has shown robust growth, climbing 3.0% in the past week and achieving a 10% increase over the last twelve months, with earnings projected to grow by 14% per annum. In this context, identifying undervalued small-cap stocks can offer potential opportunities for investors looking to capitalize on companies with promising prospects yet to be fully recognized by the broader market. Simply Wall St. ? 3 months ago EDESY NURPF ORRAF Exploring Undervalued Small Caps With Insider Action In Australia July 2024 The Australian market has shown robust performance, rising 2.1% over the last week and achieving a 10% increase over the past year with earnings expected to grow by 13% annually. In this context, identifying undervalued small-cap stocks with recent insider buying can be particularly compelling, as these actions often signal confidence in the company's future prospects amidst favorable market conditions. Simply Wall St. ? 3 months ago NURPF ORRAF ORRYY Eagers Automotive Leads Three Undervalued Small Caps With Insider Actions In Australia Amidst a buoyant Australian market, which has seen a 3.1% rise in the past week and a 10% increase over the last year with earnings projected to grow by 13% annually, investors are keenly watching for opportunities. In this environment, stocks like Eagers Automotive stand out as potentially undervalued small caps, particularly when insider actions suggest confidence in their future prospects. Simply Wall St. ? 3 months ago NURPF APE.AX EDESY Elders And 2 Other Undervalued Small Caps With Insider Action In Australia Amidst a generally buoyant Australian market where the ASX200 recently closed up by 0.9%, all sectors except IT showed positive movement. This environment, coupled with anticipations of a U.S Federal Reserve rate cut, creates an interesting backdrop for exploring undervalued opportunities within the small-cap space. In this context, understanding what constitutes a good stock can be pivotal; factors such as insider buying can often signal unrecognized value in smaller companies poised for... Simply Wall St. ? 3 months ago EDESY NURPF NCK.AX Top Undervalued Small Caps With Insider Actions In Australia July 2024 Amidst a fluctuating Australian market where the ASX200 has seen a slight decline and sectors like IT have struggled significantly, small-cap stocks continue to present unique opportunities. Particularly, certain undervalued small caps are drawing attention with insider actions suggesting potential unrecognized value in this turbulent economic landscape. In such conditions, discerning investors might look for stocks that not only show promising fundamentals but also exhibit positive insider... Simply Wall St. ? 3 months ago NURPF CODAF LCOMF Codan Leads Three Undervalued Small Caps With Insider Actions In Australia In recent trading sessions, the Australian market has shown mixed signals with the ASX200 marginally up by 0.1%. Notably, the IT sector outperformed, gaining 0.9%, while materials faced a downturn, nearly losing 1%. In such a fluctuating environment, identifying undervalued small-cap stocks like Codan that show potential for growth becomes crucial for investors looking for opportunities amidst broader market movements. Simply Wall St. ? 3 months ago NURPF CODAF CLRPF Exploring Undervalued Small Caps With Insider Actions In Australia June 2024 In recent times, the Australian market has shown a steady increase, rising 8.9% over the past year despite remaining flat in the last week. Given these conditions and with earnings expected to grow by 14% annually in the near future, undervalued small caps with insider buying actions can present intriguing opportunities for investors looking to potentially benefit from market inefficiencies. Simply Wall St. ? 3 months ago CLRPF NURPF CODAF Exploring Undervalued Small Caps With Insider Action In Australia June 2024 Amidst a backdrop of fluctuating indices, the Australian market has shown mixed signals, with sectors like utilities and communications experiencing growth while materials lag behind. This nuanced landscape sets an intriguing stage for exploring undervalued small-cap companies that may offer unique opportunities in the current economic environment. A good stock in this context would ideally demonstrate resilience and potential for growth despite broader market volatility, making it an... Simply Wall St. ? 3 months ago TABCF APE.AX NURPF Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 46%? Key Insights Neuren Pharmaceuticals' estimated fair value is AU$37.87 based on 2 Stage Free Cash Flow to Equity Current... Simply Wall St. ? 4 months ago NURPF Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as PR Newswire ? 4 months ago NURPF Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock? Most readers would already be aware that Neuren Pharmaceuticals' (ASX:NEU) stock increased significantly by 22% over... Simply Wall St. ? 7 months ago NURPF An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% Undervalued Key Insights The projected fair value for Neuren Pharmaceuticals is AU$43.02 based on 2 Stage Free Cash Flow to Equity... Simply Wall St. ? 9 months ago NURPF Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme PR Newswire ? 9 months ago NURPF Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] Return NEU.AX S&P/ASX 200 [XJO] YTD -47.42% +9.12% 1-Year +13.48% +17.03% 3-Year +573.33% +12.22%
